Oklo Inc.

New York Stock Exchange
Back to all articles
Slightly Bullish +25

$10,000 in Oklo Stock at Its High Is Worth About $2,300 Today

AI-generated analysis

📉 Oklo shares trade near $44, representing a roughly 77% drawdown from a 52-week high of $193.84.

💰 The company reported its first-ever quarterly revenue in August, amounting to approximately $1.2 million.

🏗️ This initial revenue was largely generated by businesses acquired in June rather than organic growth.

⚛️ Oklo's Groves Isotope Test Reactor in Texas reached first criticality less than a year after groundbreaking.

🇺🇸 The Groves facility is the first reactor in the DOE's Reactor Pilot Program to reach criticality on private land.

🏭 The test reactor is designed to produce isotopes for healthcare, industrial, and national security applications.

💸 Oklo has incurred approximately $153 million in losses over the past 12 months.

🚀 Management is spending faster to reduce risks around its first projects instead of slowing down operations.

📊 The company's current market value remains about 7,000 times its trailing revenue.

Bullish Signals
  • Oklo achieved a major operational milestone by reaching first criticality at its Groves Isotope Test Reactor in Texas less than a year after groundbreaking.
  • The company generated its first-ever quarterly revenue of approximately $1.2 million in August, establishing the beginnings of a services operation.
  • Oklo's Groves facility is the first reactor in the U.S. Department of Energy's Reactor Pilot Program to achieve criticality on private land.
Risk Factors
  • Oklo has incurred substantial losses totaling approximately $153 million over the past 12 months.
  • Management is currently spending faster to reduce risks around its first projects rather than slowing down, indicating ongoing financial pressure.
  • The company's current market valuation remains extremely high at roughly 7,000 times its trailing revenue.
Full Analysis
Oklo, a nuclear reactor developer trading near $44 per share, recently achieved significant operational milestones despite a substantial stock price decline of approximately 77% from its 52-week high of $193.84. The company reported its first-ever quarterly revenue in August, totaling about $1.2 million, primarily derived from engineering and consulting services following the acquisition of businesses in June. A major operational breakthrough occurred at Oklo's Groves Isotope Test Reactor in Lockhart, Texas, which reached first criticality less than a year after groundbreaking. This facility represents the first reactor in the U.S. Department of Energy's Reactor Pilot Program to achieve this status on private land, designed to produce isotopes for healthcare, industrial, and national security applications. While the company has demonstrated progress by generating revenue and successfully launching its test reactor, it continues to face significant financial challenges with losses totaling about $153 million over the past 12 months. Management is currently accelerating spending to mitigate risks associated with its first projects rather than slowing down, indicating a continued focus on execution despite the high valuation relative to current trailing revenue.